BIG PHARMA WATCH: BIG PHARMA SET NEW RECORD FOR OUT-OF-CONTROL LAUNCH PRICES IN 2023, UP 35 PERCENT FROM PREVIOUS YEAR

02-26-2024 Blog Posts

Median Price Set by Brand Name Drug Makers on New Treatments Climbs to $300,000 In case you missed it, on Friday, Reuters released a new analysis which found that the median annual price among new drugs approved by the U.S. Food and Drug Administration (FDA) in 2023 reached $300,000. This number was 35 percent higher than the […]

BIG PHARMA EARNINGS WATCH: ELI LILLY AND NOVO NORDISK

02-22-2024 Blog Posts

GLP-1 Weight-Loss Leaders “Blow Past” Wall Street Projections in Q4 2023, Hike Prices on at Least 20 Brand Name Products in First Weeks of 2024 Big Pharma giants Eli Lilly and Novo Nordisk recently reported earnings that blew past Wall Street estimates for the fourth quarter of 2023. Both brand name companies have become leaders […]

BIG PHARMA EARNINGS WATCH: MERCK, BRISTOL MYERS SQUIBB AND ABBVIE

02-15-2024 Blog Posts

More Big Pharma Giants Report Earnings That Top Wall Street Expectations While Continuing to Hike Prices on Dozens of Brand Name Drugs Merck, Bristol Myers Squibb, and AbbVie all recently reported earnings for the fourth quarter of 2023 that topped Wall Street analysts’ expectations after all three Big Pharma giants engaged in price hikes in […]

DOSE OF REALITY: BIG PHARMA CEOS FACE A RECKONING FROM LAWMAKERS AND EXPERTS ON ANTI-COMPETITIVE PRACTICES AND PRICE GOUGING

02-12-2024 Blog Posts

Patent Abuse Designed to Extend Monopolies, Block Competition and Keep Prices High Takes Center Stage at HELP Committee Hearing On Thursday, the U.S. Senate Committee on Health, Education, Labor and Pensions (HELP) held a hearing with the CEOs of three Big Pharma giants: Johnson & Johnson, Merck and Bristol Myers Squibb. During the hearing, lawmakers, […]

BIG PHARMA EARNINGS WATCH: PFIZER & GLAXOSMITHKLINE

02-9-2024 Blog Posts

Big Pharma Giants Continue Q4 Earnings Besting Wall Street Expectations Pfizer and GlaxoSmithKline (GSK) are the latest Big Pharma giants to report Wall Street-besting earnings for the fourth quarter of 2023. Both companies topped analysts’ expectations after hiking prices on blockbuster products throughout the year. One key area for both companies was their recently launched […]

DOSE OF REALITY: BIG PHARMA BUILDING PATENT THICKETS DISCONNECTED FROM ACTUAL INNOVATION TO CREATE NEW MONOPOLIES ON GLP-1 WEIGHT LOSS DRUGS

02-8-2024 Blog Posts

JAMA Analysis Finds Patents for Active Ingredients for Weight Loss Drugs Significantly Lower than for Other Prescription Drugs That Rely on Drug-Device Combinations A new analysis published in JAMA Network finds that the brand name drug makers marketing a new category of weight loss drugs, glucagon-like peptide 1 (GLP-1) receptor agonists, are increasingly utilizing device […]

BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON

01-31-2024 Blog Posts

Big Pharma Giant Kicks Off Q4 Earnings After Hiking Prices More Than 40 Times in 2023 This past week, brand name drug giant Johnson & Johnson kicked off the first round of Big Pharma earnings calls for the fourth quarter of 2023. The company surpassed Wall Street analysts’ earnings and profit expectations after hiking prices […]

DOSE OF REALITY: BIG PHARMA’S EGREGIOUS PRICING PRACTICES AND ANTI-COMPETITIVE TACTICS DRIVE HIGHER HEALTH CARE COSTS

01-30-2024 Blog Posts

Big Pharma Price Hikes, Rising Launch Prices And Patent Abuse Impose Massive Costs on Patients, Taxpayers, and the U.S. Health Care System Tomorrow, the U.S. House Committee on Energy and Commerce Health Subcommittee is scheduled to hold a hearing to discuss health care spending in the United States. Ahead of the hearing on this important topic, get […]

BIG PHARMA WATCH: AARP REPORT SHINES LIGHT ON SCALE AND COST OF BIG PHARMA’S PRICE HIKES THAT EXCEED INFLATION

01-19-2024 Blog Posts

Rx Price Watch Analysis Finds Big Pharma Price Increases Outpaced Inflation Every Year Except One Between 2006 and 2020 A new report from AARP finds Big Pharma “consistently” increased prices above the rate of inflation between 2006 and 2020. In fact, the report found that Big Pharma increased prices on 943 blockbuster drugs widely used […]

BIG PHARMA WATCH: BIG PHARMA DELAYS NEW DRUGS THAT COULD HELP PATIENTS TO BOOST PROFITS

01-8-2024 Blog Posts

Report Finds Several Brand Name Drug Companies Waiting to Introduce New Products Until They Can Get Approval for More Lucrative Disease Classes  It appears egregious price hikes on existing prescription drugs, out-of-control prices on new products and anti-competitive schemes to extend monopolies just aren’t enough to satisfy Big Pharma’s appetite for putting profits over patients. […]

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.